Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK: A Chronic Kidney Disease Markov Model

Author： Nuijten Mark  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.8, 2010-08, pp. : 545-557

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease

By  

Current Drug Targets, Vol. 15, Iss. 7, 2014-06 ,pp. : 703-709

Bentham Science Publishers

Access to resources Recommend Favorite

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

By Cheng Steven   Coyne Daniel  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 617-621

Informa Healthcare

Access to resources Recommend Favorite

Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism: Understanding the Differences Among Therapies

By Brancaccio Diego  

Drugs, Vol. 67, Iss. 14, 2007-01 ,pp. : 1981-1998

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

By Jansen Jeroen P.  

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 323-344

Adis International

Access to resources Recommend Favorite

Management of Secondary Hyperparathyroidism in the Elderly Patient with Chronic Kidney Disease

By Cozzolino Mario   Gallieni Maurizio   Pasho Sabina   Fallabrino Giuditta   Ciceri Paola   >   Olivi Laura   Brancaccio Diego  

Drugs & Aging, Vol. 26, Iss. 6, 2009-06 ,pp. : 457-468

Adis International

Access to resources Recommend Favorite